Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
20.59
+0.05 (0.24%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Genmab Employees
Genmab had 2,678 employees as of December 31, 2024. The number of employees increased by 474 or 21.51% compared to the previous year.
Employees
2,678
Change (1Y)
474
Growth (1Y)
21.51%
Revenue / Employee
$1,115,865
Profits / Employee
$406,617
Market Cap
12.78B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,678 | 474 | 21.51% |
Dec 31, 2023 | 2,204 | 544 | 32.77% |
Dec 31, 2022 | 1,660 | 448 | 36.96% |
Dec 31, 2021 | 1,212 | 431 | 55.19% |
Dec 31, 2020 | 781 | 233 | 42.52% |
Dec 31, 2019 | 548 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GMAB News
- 4 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 11 days ago - Genmab's Outlook Beyond Darzalex's Patent Cliff - Seeking Alpha
- 11 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 - GlobeNewsWire
- 15 days ago - Genmab A/S Share Capital Reduction - GlobeNewsWire
- 19 days ago - Transactions In Connection with Share Buy-back Program - GlobeNewsWire
- 24 days ago - Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - GlobeNewsWire
- 25 days ago - TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer - GlobeNewsWire
- 26 days ago - Transactions in connection with share buy-back program - GlobeNewsWire